2. UroToday Home
  3. Transformative Evidence
  4. The VISION Trial: Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
  5. Articles
  6. UroToday
  7. Prostate Cancer

A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy - Beyond the Abstract

The pivotal phase 3 VISION study used [68Ga]Ga-PSMA-11 (also known as 68Ga-PSMA-11) imaging to identify patients with metastatic castration-resistant prostate cancer eligible for [177Lu]Lu-PSMA-617 radioligand therapy, based on predefined read criteria. In this substudy of VISION, the inter-reader variability and intra-reader reproducibility of visual assessments of 68Ga-PSMA-11 positron emission tomography scans using the VISION read criteria were evaluated.

A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy - Beyond the Abstract



Phillip Kuo, MD, PhD, Professor of Medical Imaging, Medicine and Biomedical Engineering, University of Arizona, Tucson, Arizona

Read the Abstract